Patents by Inventor Susan Aster

Susan Aster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
    Publication number: 20060258695
    Abstract: Triazole derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
    Type: Application
    Filed: May 26, 2004
    Publication date: November 16, 2006
    Inventors: Sherman Waddell, Gina Santorelli, Milana Maletic, Aaron Leeman, Xin Gu, Donald Graham, James Balkovec, Susan Aster
  • Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
    Publication number: 20050245588
    Abstract: The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: September 17, 2003
    Publication date: November 3, 2005
    Inventors: Amjad Ali, Susan Aster, James Balkovec, Donald Graham, Julianne Hunt, Florida Kallashi, Peter Sinclair, James Tata, Gayle Taylor, Joung Goulet
  • Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
    Publication number: 20050154038
    Abstract: Triazole derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
    Type: Application
    Filed: December 14, 2004
    Publication date: July 14, 2005
    Inventors: Sherman Waddell, Gina Santorelli, Milana Maletic, Aaron Leeman, Xin Gu, Donald Graham, James Balkovec, Susan Aster
  • 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
    Publication number: 20050070720
    Abstract: Compounds having Formula (I), including pharmaceutically acceptable salts and prodrugs thereof: are selective inhibitors of the 11?-HSD1 enzyme. They inhibit the 11?-HSD1-mediated conversion of cortisone and other 11-keto-glucocorticoids to cortisol and other 11?-hydroxy-glucocorticoids. The 11?-HSD1 inhibitors therefore decrease the amount of cortisol in target tissues, thereby modulating the effects of cortisol. Modulation of cortisol may be effective in controlling non-insulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM or with excess cortisol in the body.
    Type: Application
    Filed: January 28, 2003
    Publication date: March 31, 2005
    Inventors: James Balkovec, Rolf Thieringer, Steven Mundt, Anne Hermanowski-Vosatka, Donald Graham, Gool Patel, Susan Aster, Sherman Waddell, Steven Olson, Milana Maletic